Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

The deal will see Germany's Boehringer pay Sanofi €4.7 billion as part of the deal, with Merial valued at €11.4 billion and its global consumer health (CHC) division – except its business in ...

Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of ...

Sanofi has plans to separate its Consumer Healthcare [“CHC”] unit through the creation of a publicly listed entity headquartered in Paris called Opella. Sanofi intends to sell a controlling ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...